Rachael M Zemek

7PUBLICATIONS
19CO-AUTHORS
Tumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)Australian literature (excl. Aboriginal and Torres Strait Islander literature)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 17, 2024
Exploiting temporal aspects of cancer immunotherapy.

Rachael M Zemek, Valsamo Anagnostou, Inês Pires da Silva

|May 03, 2024
Time-course RNAseq data of murine AB1 mesothelioma and Renca renal cancer following immune checkpoint therapy.

Wee Loong Chin, Rachael M Zemek, Caitlin M Tilsed

|Sep 11, 2023
Celebrating 100 years of Immunology & Cell Biology - a special focus on the field of tumor immunology in Australia.

Snehlata Kumari, Rachael M Zemek, Umaimainthan Palendira

|May 05, 2023
Geldanamycin treatment does not result in anti-cancer activity in a preclinical model of orthotopic mesothelioma.

M Lizeth Orozco Morales, Catherine A Rinaldi, Emma de Jong

|Aug 19, 2022
Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice.

Rachael M Zemek, Wee Loong Chin, Vanessa S Fear

|Apr 03, 2020
Bilateral murine tumor models for characterizing the response to immune checkpoint blockade.

Rachael M Zemek, Vanessa S Fear, Cath Forbes

Pageof 2